Read by QxMD icon Read

bioresorbable implant

Jarosław Hiczkiewicz, Sylwia Iwańczyk, Aleksander Araszkiewicz, Magdalena Łanocha, Dariusz Hiczkiewicz, Stefan Grajek, Maciej Lesiak
BACKGROUND: The PSP (predilatation, sizing, post-dilatation)-technique was developed to improve the prognosis of patients after bioresorbable vascular scaffold (BVS) implantation. In acute coronary syndrome (ACS) the use of BVS is particularly demanding and carries some potential risk regarding aggressive lesion preparation, proper vessel sizing due to spasm and thrombus inside the artery. The aim herein, was to determine the long-term results of BVS stenting in ACS patients depending on the scaffold implantation technique...
February 14, 2019: Cardiology Journal
Shintaro Sukegawa, Hotaka Kawai, Keisuke Nakano, Takahiro Kanno, Kiyofumi Takabatake, Hitoshi Nagatsuka, Yoshihiko Furuki
Purpose : We aimed to document the clinical usefulness of uncalcined and unsintered hydroxyapatite (u-HA) particles and poly-L-lactide (PLLA) composite materials and their advantageous properties. Methods : Between April 2016 and March 2018, five patients required anterior maxillary alveolar ridge augmentation using fixation with u-HA/PLLA screws for an onlay block bone graft harvested from the mandibular ramus at our institute. Bone biopsies were obtained from the dental implantation site following bone healing for histomorphometric and immunohistochemical (IHC) measurements...
2019: International Journal of Medical Sciences
Lukasz Koltowski, Mariusz Tomaniak, Lisa Gross, Bartosz Rymuza, Michal Kowara, Radoslaw Parma, Anna Komosa, Mariusz Klopotowski, Claudius Jacobshagen, Tommaso Gori, Daniel Aradi, Kurt Huber, Martin Hadamitzky, Steffen Massberg, Maciej Lesiak, Krzysztof J Filipiak, Adam Witkowski, Grzegorz Opolski, Zenon Huczek, Dirk Sibbing
To investigate the safety and efficacy of an early platelet function testing (PFT)-guided de-escalation of dual antiplatelet treatment (DAPT) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with bioresorbable vascular scaffolds (BVS). Early DAPT de-escalation is a new non-inferior alternative to 12-months DAPT in patients with biomarker positive ACS treated with stent implantation. In this post-hoc analysis of the TROPICAL-ACS trial, which randomized 2610 ACS patients to a PFT-guided DAPT de-escalation (switch from prasugrel to clopidogrel) or to control group (uniform prasugrel), we compared clinical outcomes of patients (n = 151) who received a BVS during the index PCI...
February 9, 2019: Journal of Thrombosis and Thrombolysis
Yuhei Nojima, Hidenori Adachi, Madoka Ihara, Tetsuya Kurimoto, Keita Okayama, Yasushi Sakata, Shinsuke Nanto
OBJECTIVES: We aimed to compare the coronary angioscopic appearance of neointimal coverage (NIC) over durable-polymer everolimus-eluting stents (XIENCE-EES) and bioresorbable-polymer everolimus-eluting stents (SYNERGY-EES) 1 year after implantation. BACKGROUND: XIENCE-EES and SYNERGY-EES have been developed to prevent delayed arterial healing associated with first generation drug-eluting stents. However, the process of arterial healing after XIENCE-EES and SYNERGY-EES implantation has not been clarified...
February 9, 2019: Catheterization and Cardiovascular Interventions
Keir McCutcheon, Johan Bennett, Thomas Marynissen, Tom Adriaenssens
No abstract text is available yet for this article.
February 8, 2019: Acta Cardiologica
Jian-Feng Zheng, Hong Qiu, Yuan Tian, Xiao-Ying Hu, Tong Luo, Chao Wu, Yi Tian, Yue Tang, Lai-Feng Song, Li Li, Liang Xu, Bo Xu, Run-Lin Gao
OBJECTIVES: The aim of this study was to investigate the operability, 6-month efficacy, and safety of the novel sirolimus-eluting iron bioresorbable coronary scaffold (IBS) system compared with a cobalt-chromium everolimus-eluting stent (EES) (XIENCE Prime stent) in porcine coronary arteries. BACKGROUND: Bioresorbable scaffolds have been considered the fourth revolution in percutaneous coronary intervention. However, the first-generation bioresorbable scaffold showed suboptimal results...
February 11, 2019: JACC. Cardiovascular Interventions
Roman Marchenko, Salik Nazir, Shelina Malla, Anthony Donato
Revascularization of chronic total occlusions (CTO) with percutaneous coronary intervention is associated with favorable long-term clinical and echocardiographic outcomes. Whether bioresorbable vascular scaffolds (BVS) would be advantageous in the treatment of CTO is unknown as patients with these lesions were generally excluded from large BVS randomized trials. We performed a systematic review, which sought to summarize known data on mid- to long-term clinical outcomes for BVS in CTO. We searched MEDLINE, EMBASE, clinicaltrials...
November 28, 2018: Curēus
Dakota M Binkley, Bryan E J Lee, Sokunthearath Saem, Jose Manuel Moran-Mirabal, Kathryn Grandfield
Implanted devices are prone to bacterial infections, which can result in implant loosening and device failure. Mitigating these infections is important to both implant stability and patient health. The development of antibacterial implant coatings can decrease the presence of bacterial colonies, reducing the risk for bacterial-dependent implant failure. Here, we show that electrospun polycaprolactone (PCL) fibers doped with silver nanoparticles (NPs) from a silver nitrate precursor have the potential to decrease the prevalence of Streptococcus pneumoniae (S...
February 4, 2019: Nanotechnology
Madeleine Chagnon, Louis-Georges Guy, Nicolette Jackson
Absorbable metallic implants have been under investigation for more than a century. Animal and human studies have shown that magnesium (Mg) alloys can be safely used in bioresorbable scaffolds. Several cardiovascular and orthopedic biodegradable metallic devices have recently been approved for use in humans. Bioresorbable Mg implants present many advantages when compared to bioabsorbable polymer or nonabsorbable metallic implants, including similar strength and mechanical properties as existing implant-grade metals without the drawbacks of permanence or need for implant removal...
February 3, 2019: Toxicologic Pathology
Kai Narita, Qiaomu Tian, Ian Johnson, Chaoxing Zhang, Equo Kobayashi, Huinan Liu
Magnesium (Mg)-based materials have shown great potentials for bioresorbable implant applications. Previous studies showed that Mg with 10 and 20 vol % β-tricalcium phosphate (β-TCP) composites produced by spark plasma sintering, improved mechanical properties when compared with pure Mg. The objectives of this study were to evaluate the degradation behaviors of Mg/10% β-TCP and Mg/20% β-TCP composites in revised stimulated body fluid (rSBF), and to determine their cytocompatibility with bone marrow derived mesenchymal stem cells (BMSCs) using the direct culture method...
February 1, 2019: Journal of Biomedical Materials Research. Part B, Applied Biomaterials
Enrico Frigoli, Pieter Smits, Pascal Vranckx, Yokio Ozaki, Jan Tijssen, Peter Jüni, Marie-Claude Morice, Yoshinobu Onuma, Stephan Windecker, Andrè Frenk, Christian Spaulding, Bernard Chevalier, Emanuele Barbato, Pim Tonino, David Hildick-Smith, Marco Roffi, Ran Kornowski, Carl Schultz, Maciej Lesiak, Andrés Iñiguez, Antonio Colombo, Mirvat Alasnag, Ajit Mullasari, Stefan James, Goran Stankovic, Paul J L Ong, Alfredo E Rodriguez, Felix Mahfoud, Jozef Bartunek, Aris Moschovitis, Peep Laanmets, Sergio Leonardi, Dik Heg, Mikael Sunnåker, Marco Valgimigli
BACKGROUND: The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear. DESIGN: MASTER DAPT (clinicaltrial.govNCT03023020) is an investigator-initiated, open-label, multicenter, randomized controlled trial comparing an abbreviated versus a standard duration of antiplatelet therapy after bioresorbable polymer-coated Ultimaster (TANSEI) sirolimus-eluting stent implantation in approximately 4,300 HBR patients recruited from ≥100 interventional cardiology centers globally...
November 22, 2018: American Heart Journal
Taku Asano, Jarkko Hytönen, Ply Chichareon, Jouni Taavitsainen, Norihiro Kogame, Yuki Katagiri, Yosuke Miyazaki, Kuniaki Takahashi, Rodrigo Modolo, Hidenori Komiyama, Erhan Tenekecioglu, Yohei Sotomi, Joanna J Wykrzykowska, Jan J Piek, John Martin, Andreas Baumbach, Anthony Mathur, Yoshinobu Onuma, Seppo Ylä-Herttuala, Patrick W Serruys
BACKGROUND: Little is known about serial changes in lumen and device dimensions after bioresorbable scaffold implantation in a growing animal model. Methods and Results: ABSORB (n=14) or bare metal stents (ICROS amg [Abbott Vascular, Santa Clara, CA, USA], Winsen-Luhe, Germany; n=15) were implanted in the coronary arteries of domestic swine (a hybrid of Finnish-Norwegian Landrace swine) weighing 30-35 kg. Angiography and optical coherence tomography (OCT) were performed immediately after implantation and repeated at 7 days, 1, 3, 6 and 12 months after the index procedure...
January 31, 2019: Circulation Journal: Official Journal of the Japanese Circulation Society
Donghui Zhu, Irsalan Cockerill, Yingchao Su, Zhaoxiang Zhang, Jiayin Fu, Kee-Won Lee, Jun Ma, Chuka Okpokwasili, Liping Tang, Yufeng Zheng, Yi-Xian Qin, Yadong Wang
Zn-based biomaterials have emerged as promising new types of bioresorbable metallics applicable to orthopedic devices, cardiovascular stents, and other medical applications recently. Compared to other degradable metallic biomaterials (i.e. Mg- or Fe-based), Zn biomaterials have a more appropriate corrosion rate without hydrogen gas evolution. Here, we evaluated the potential of Zn-based metallics as medical implants, both in vitro and in vivo, alongside a standard benchmark Mg alloy, AZ31. The mechanical properties of the pure Zn were not strong enough, but were significantly enhanced (microhardness >70 kg/mm2, strength >220 MPa, elongation >15%) after alloying with Sr or Mg (1...
January 29, 2019: ACS Applied Materials & Interfaces
Qiaomu Tian, Jiajia Lin, Laura Rivera-Castaneda, Amit Tsanhani, Zachary S Dunn, Alexis Rodriguez, Arash Aslani, Huinan Liu
Magnesium (Mg) and its alloys have shown attractive biocompatibility and mechanical strength for medical applications, but low corrosion resistance of Mg in physiological environment limits its broad clinical translation. Hydroxyapatite (HA) nanoparticles (nHA) are promising coating materials for decreasing degradation rates and prolonging mechanical strength of Mg-based implants while enhancing bone healing due to their osteoconductivity and osteoinductivity. Conformal HA coatings with nano-to-submicron structures, namely nHA and mHA coatings, were deposited successfully on Mg plates and rods using a transonic particle acceleration (TPA) process under two different conditions, characterized, and investigated for their effects on Mg degradation in vitro...
January 28, 2019: Scientific Reports
Kazuaki Morizane, Yasuo Shikinami, Shunsuke Fujibayashi, Koji Goto, Bungo Otsuki, Toshiyuki Kawai, Takayoshi Shimizu, Shuichi Matsuda
A bone fixation device made of unsintered hydroxyapatite (u-HA) particles uniformly dispersed in a poly-l-lactide matrix and reinforced by compressive forging (uniformly dispersed composite; UDC) has been clinically applied in several fields. However, it has reported some foreign body reactions over a long implantation period due to its slow bioresorbability. To further enhance its bioresorbability, we developed devices comprising a fibrous assembly of poly-l-lactide only three-dimensionally intertwined with particulate hydroxyapatite/poly-l-lactide composite...
April 2019: Materials Science & Engineering. C, Materials for Biological Applications
Rajiv Rampat, Timothy Williams, Thomas Mayo, Manuela Mengozzi, Pietro Ghezzi, David Hildick-Smith, James Cockburn
INTRODUCTION: The ABSORB bioresorbable vascular scaffold (BVS) is associated with greater neointimal proliferation and thrombotic rate than the metal stent. The role of inflammatory biomarkers on neointimal proliferation has not been studied in the setting of BVS implantation. PATIENTS AND METHODS: Thirty patients had arterial blood sampling before elective percutaneous coronary intervention with the ABSORB BVS and at 9-months follow-up. Plasma levels of interleukin-6, soluble CD40 ligand, monocyte chemotactic protein-1 and C-reactive protein were measured using enzyme-linked immunosorbent assay...
January 22, 2019: Coronary Artery Disease
Joo Yeon Kim, Tae Young Jung, Jae Hwan Kwon
BACKGROUND: The aim of the study was to compare the effectiveness of endoscopic endonasal reduction using a bioresorbable panel and silastic sheet packed with Merocel for blowout fractures of the medial orbital wall. DESIGN: Retrospective study. METHODS: The study group consisted of 147 patients who underwent endoscopic endonasal reduction of a blowout fracture of the medial orbital wall between January 2005 and December 2016. Fifty-seven fractures were repaired using a splint formed by a silastic sheet and Merocel (splint group), whereas 90 fractures were repaired using a bioresorbable panel for interposition (interposition group)...
January 17, 2019: Journal of Craniofacial Surgery
Christine Reichart, Jochen Wöhrle, Sinisa Markovic, Wolfgang Rottbauer, Julia Seeger
BACKGROUND: Data on bioresorbable vascular scaffolds (BVS) for the treatment of long lesions are limited. We studied the use of BVS-Absorb in routine clinical practice and compared the outcome of long lesions with short lesions. Implantation of drug-eluting scaffolds without PSP-technique (predilation, proper sizing and postdilation) is associated with an increased thrombotic risk. We compared the long-term outcome up to 36 months of patients with short (< 20 mm) and long (≥20 mm) coronary artery lesions after implantation of bioresorbable vascular scaffolds (BVS) via PSP-technique...
January 18, 2019: BMC Cardiovascular Disorders
Nicolette Jackson, Michel Assad, Derick Vollmer, James Stanley, Madeleine Chagnon
Orthopedic medical devices are continuously evolving for the latest clinical indications in craniomaxillofacial, spine, trauma, joint arthroplasty, sports medicine, and soft tissue regeneration fields, with a variety of materials from new metallic alloys and ceramics to composite polymers, bioresorbables, or surface-treated implants. There is great need for qualified medical device pathologists to evaluate these next generation biomaterials, with improved biocompatibility and bioactivity for orthopedic applications, and a broad range of knowledge is required to stay abreast of this ever-changing field...
January 17, 2019: Toxicologic Pathology
Zisis Dimitriadis, Alberto Polimeni, Remzi Anadol, Martin Geyer, Melissa Weissner, Helen Ullrich, Thomas Münzel, Tommaso Gori
The technique used at the time of implantation has a central role in determining the risk of thrombosis in bioresorbable vascular scaffolds (BRS). Different definitions of the "optimal" implantation technique exist, however. The impact of individual procedural characteristics on the risk of scaffold thrombosis (ScT) was evaluated in a single-center observational study that enrolled 657 patients (79% males, mean age 63 ± 12 years) with 763 lesions who received a total of 925 BRS for de novo lesions...
January 15, 2019: Journal of Clinical Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"